LON:AVOAdvanced Oncotherapy Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Advanced Oncotherapy PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 25.20 +0.20 (+0.80 %) (As of 07/14/2020) Add Compare Share Today's Range 24.61Now: GBX 25.20▼ 25.4050-Day Range 24.50MA: GBX 25.75▼ 2752-Week Range 0.26Now: GBX 25.20▼ 44Volume77,456 shsAverage Volume79,755 shsMarket Capitalization£77.21 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Advanced Oncotherapy PLC, together with its subsidiaries, focuses on providing radiotherapy systems for the treatment of cancer. The company operates through two segments, Proton Therapy and Healthcare Related Properties. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. The company also rents a medical facility. It has operations in the United Kingdom, Switzerland, and the Unites States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy PLC was incorporated in 2005 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAdvanced Oncotherapy has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 155, Advanced Oncotherapy has a potential upside of 515.1% from its current price of GBX 25.20.Amount of Analyst CoverageAdvanced Oncotherapy has received no research coverage in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesAdvanced Oncotherapy has received 188 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAdvanced Oncotherapy has received 243 “underperform” votes. (Add your “underperform” vote.)Community SentimentAdvanced Oncotherapy has received 56.38% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy and other stocks. Vote “Outperform” if you believe AVO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AVO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAdvanced Oncotherapy does not currently pay a dividend.Dividend GrowthAdvanced Oncotherapy does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Advanced Oncotherapy insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Advanced Oncotherapy is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Advanced Oncotherapy is -2.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdvanced Oncotherapy has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.14 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Medical Devices Sub-IndustryN/A SectorMedical Current SymbolLON:AVO Previous Symbol CUSIPN/A CIKN/A Webwww.advancedoncotherapy.com Phone+44-20-36178728Debt Debt-to-Equity Ratio108.32 Current Ratio3.43 Quick Ratio0.83Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 1.09 per share Price / Cash Flow23.18 Book ValueGBX 17.60 per share Price / Book1.43Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees93 Outstanding Shares306,371,008Market Cap£77.21 million Next Earnings DateN/A OptionableNot Optionable GBX 25.20 +0.20 (+0.80 %) (As of 07/14/2020) 30 days | 90 days | 365 days | Advanced Chart Receive AVO News and Ratings via Email Sign-up to receive the latest news and ratings for AVO and its competitors with MarketBeat's FREE daily newsletter. Advanced Oncotherapy (LON:AVO) Frequently Asked Questions How has Advanced Oncotherapy's stock been impacted by COVID-19 (Coronavirus)? Advanced Oncotherapy's stock was trading at GBX 32.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVO stock has decreased by 22.5% and is now trading at GBX 25.20. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Advanced Oncotherapy? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advanced Oncotherapy in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Advanced Oncotherapy. How were Advanced Oncotherapy's earnings last quarter? Advanced Oncotherapy PLC (LON:AVO) posted its quarterly earnings results on Monday, June, 29th. The company reported ($9.83) earnings per share for the quarter, missing analysts' consensus estimates of ($8.90) by $0.93. View Advanced Oncotherapy's earnings history. What price target have analysts set for AVO? 1 Wall Street analysts have issued 12-month price objectives for Advanced Oncotherapy's shares. Their forecasts range from GBX 155 to GBX 155. On average, they anticipate Advanced Oncotherapy's stock price to reach GBX 155 in the next twelve months. This suggests a possible upside of 515.1% from the stock's current price. View analysts' price targets for Advanced Oncotherapy. Has Advanced Oncotherapy been receiving favorable news coverage? News coverage about AVO stock has trended somewhat negative recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Advanced Oncotherapy earned a coverage optimism score of -1.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news about Advanced Oncotherapy. Who are some of Advanced Oncotherapy's key competitors? Some companies that are related to Advanced Oncotherapy include Creo Medical Group (CREO), Hamilton Thorne (HTL), Imricor Med SYS Cdi 1:1 US Person Prohibited Excluding QIB (IMR), Medica Group (MGP), Electromed (ELMD), Electromed (ELMD), Cyclopharm (CYC), Patient Home Monitoring (PTQ), Titan Medical (TMD), Somnomed (SOM), Resonance Health (RHT), REVA Medical (RVA), MRI Interventions (CLPT), Total Brain (TTB) and EMvision Medical Devices (EMV). View all competitors. What other stocks do shareholders of Advanced Oncotherapy own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advanced Oncotherapy investors own include UK Oil & Gas (UKOG), Avesoro Resources (ASO), BMR Group (BMR), GW Pharmaceuticals PLC- (GWPH), Lancashire (LRE), Oxford BioMedica (OXB), Sirius Minerals (SXX), Renishaw (RSW), Scancell (SCLP) and Tullow Oil (TLW). Who are Advanced Oncotherapy's key executives? Advanced Oncotherapy's management team includes the following people: Dr. Michael Jeffrey Sinclair, Exec. Chairman (Age 76)Mr. Nicolas Serandour, CEO & Exec. DirectorMr. Ed Lee, COO & Sr. VP of OperationsMr. Graham Pughe, Sr. Vice-Pres, Accounting & ITMs. Geraldine Poindron, Corp. Fin. Mang. What is Advanced Oncotherapy's stock symbol? Advanced Oncotherapy trades on the London Stock Exchange (LON) under the ticker symbol "AVO." How do I buy shares of Advanced Oncotherapy? Shares of AVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Advanced Oncotherapy's stock price today? One share of AVO stock can currently be purchased for approximately GBX 25.20. How big of a company is Advanced Oncotherapy? Advanced Oncotherapy has a market capitalization of £77.21 million. Advanced Oncotherapy employs 93 workers across the globe. What is Advanced Oncotherapy's official website? The official website for Advanced Oncotherapy is www.advancedoncotherapy.com. How can I contact Advanced Oncotherapy? Advanced Oncotherapy's mailing address is Third Fl Clearwater HSE, 4-7 Manchester Street, LONDON, W1U 3AE, United Kingdom. The company can be reached via phone at +44-20-36178728. This page was last updated on 8/4/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
